Introduction {#section5-1179554917743981}
============

Cancer remains the second leading cause of death in the United States, although current trends show the incidence of many cancers are declining.^[@bibr1-1179554917743981]^ The incidence of renal cell carcinoma (RCC), however, has been rising steadily, increasing 2% to 4% per year.^[@bibr2-1179554917743981]^ Renal cell carcinoma is the most common type of kidney cancer and is the seventh most common cancer overall among men.^[@bibr1-1179554917743981]^ Renal cell carcinoma is curable with surgery, but many organs including the lungs, liver, bone, and the thyroid gland have the propensity to house metastatic cells from the kidney. Approximately one-third of patients will have metastatic disease at diagnosis and a quarter of patients will develop metastasis after curative-intent nephrectomy. Unfortunately, despite numerous therapeutic advances in recent years, the prognosis for metastatic RCC is poor, with a median survival of only about 2 years and a 5-year survival rate of less than 10%.^[@bibr3-1179554917743981]^ Early detection of RCC is paramount, but few patients present with recognizable symptoms, making an early diagnosis difficult.

Metastasis to the thyroid is relatively rare, despite its rich blood supply. Renal cell carcinoma, however, is one of the more common types of neoplasms to metastasize to the thyroid.^[@bibr4-1179554917743981],[@bibr5-1179554917743981]^ Little is understood about the mechanism of metastasis or the potentially advantageous environment of the thyroid for RCC cells. Further barriers to understanding this relationship arise from the stochastic nature of disease progression, as some patients present with RCC and no signs of thyroid involvement until years later, whereas others present with thyroid metastasis before clinically appreciable kidney cancer.^[@bibr4-1179554917743981]^ On a genomic level, there is mutational heterogeneity between the primary tumor and the metastatic sites.^[@bibr6-1179554917743981]^ Furthermore, prognostic implications after thyroid metastasis are unclear. Studies attempting to determine prognosis after thyroid involvement have been limited by low numbers of patients and a variety of treatment approaches.^[@bibr5-1179554917743981],[@bibr7-1179554917743981][@bibr8-1179554917743981][@bibr9-1179554917743981][@bibr10-1179554917743981]--[@bibr11-1179554917743981]^

In an effort to better characterize this patient population, we conducted a retrospective study analyzing patients with pathologically confirmed RCC metastasis to the thyroid gland at Wake Forest Baptist Medical Center (WFBMC). In addition, we performed a systematic review of the literature to identify additional cases of thyroid metastases from RCC. We hypothesized that patients with RCC metastasis to the thyroid gland would have improved survival compared with patients with other patterns of metastasis.

Materials and Methods {#section6-1179554917743981}
=====================

Institutional cohort {#section7-1179554917743981}
--------------------

To capture all patients with RCC metastasis to the thyroid at WFBMC, we obtained Institutional Review Board (IRB) approval and searched the cancer registry and hospital tumor bank back to 2005. Our initial query produced 11 patients. After reviewing the patient charts, 4 cases were excluded as they had suggestive imaging but no pathologic confirmation of thyroid metastasis. From the remaining 7 patients, data were extracted regarding demographics, pathology, time course of disease and metastasis, site of metastasis, laboratory results, family history of cancer, and cancer treatment. Descriptive statistics were used summarize the WFBMC cohort. Overall survival (OS) was summarized using Kaplan-Meier methods.

Literature review cohort {#section8-1179554917743981}
------------------------

As shown in [Figure 1](#fig1-1179554917743981){ref-type="fig"}, we conducted a literature search using PubMed with the following search criteria: ("Thyroid Neoplasms"\[Mesh\]) AND "Carcinoma, Renal Cell"\[Mesh\] Filters: Humans, English). The original search produced 158 papers. The search results were further limited to papers published between January 2005 and July 2015, to capture data from patients in the era of vascular endothelial growth factor--directed therapy. This excluded 73 papers. Bibliographies of all reviewed articles were searched to identify additional relevant titles. Only studies with 5 or more patients were included to limit reporting bias. Furthermore, only studies that reported patient-level data such as age at nephrectomy, interval between nephrectomy and thyroid metastasis, and OS were included. Applying these criteria, only 6 papers remained, reporting on a total of 72 patients.^[@bibr5-1179554917743981],[@bibr7-1179554917743981][@bibr8-1179554917743981][@bibr9-1179554917743981][@bibr10-1179554917743981]--[@bibr11-1179554917743981]^ Descriptive statistics were used summarize the findings. The Kaplan-Meier method was used to calculate OS.

![PubMed search strategy for papers describing at least 5 patients with renal cell carcinoma metastasis to the thyroid gland.](10.1177_1179554917743981-fig1){#fig1-1179554917743981}

Results {#section9-1179554917743981}
=======

Institutional cohort {#section10-1179554917743981}
--------------------

Seven patients with pathologically confirmed RCC metastasis to the thyroid gland were identified from the institutional query, 5 men and 2 women. Of all the patients, 6 were white, 1 was African American. Three patients had a first-degree relative with cancer, although none had cancer of the kidney or the thyroid gland. Two patients had a family history of nonneoplastic thyroid disease (hypothyroidism). Four patients underwent systemic therapy for treatment of RCC, and 5 of the 7 patients had either partial or total thyroidectomy after metastasis. The age range at initial RCC diagnosis for these patients was 39 to 61 years, with the average age being 52.4 years. The median interval between RCC diagnosis and thyroid metastasis was 58.1 months. Two patients had metastasis exclusively to glandular organs (adrenal, thyroid), whereas the others had metastasis to both glandular and nonglandular organs. All but one patient had metastasis to organs other than the thyroid. The median follow-up time from date of RCC diagnosis to date of last follow-up (n = 5) or death (n = 2) was 53 months.

The median OS for the WFBMC cohort was 56.4 months (95% confidence interval \[CI\]: 0.6-10.5). Median survival after RCC metastasis to the thyroid was 21.5 months. Overall survival for patients with glandular-only metastasis was prolonged compared with those with thyroid plus nonglandular metastasis; however, this was skewed by one outlier in a very small sampling of patients. That patient was a white woman who was diagnosed with RCC at age 39 and thyroid metastasis occurred 14.4 years later. When she was younger, she had been diagnosed with and treated for acute lymphoblastic leukemia. Her RCC treatment course included thyroidectomy and adrenalectomy with no systemic therapy. She was the only patient with the Xp11 translocation variant of RCC in the cohort. Translocation carcinoma is thought to be a more aggressive RCC variant^[@bibr12-1179554917743981]^; however, she continues to do well, suggesting that location of metastasis may be more predictive than molecular subtype in some cases. [Table 1](#table1-1179554917743981){ref-type="table"} provides patient-level data from the WFBMC cohort.

###### 

Description of patients with RCC metastasis to the thyroid gland from WFBMC.

![](10.1177_1179554917743981-table1)

  Clinical characteristics of WFBMC cohort                                                                                                                                                             
  ------------------------------------------ ---- --- ----- ------------------------------------------------------ ----- ----------------------------------------------------------------------------- ----------
  1                                          61   M   45    **Thyroid**, lung                                      56    Thyroidectomy                                                                 Alive
  2                                          50   M   17    Thyroid, brain                                         38    No thyroid treatment, radiation (brain), sorafenib, sunitinib, temsirolimus   Deceased
  3                                          57   F   2     Thyroid, lung, pelvis                                  7     Radiation to thyroid, radiation to pelvis, temsirolimus, sunitinib            Deceased
  4                                          58   M   99    Thyroid, lung, **adrenal**                             126   Thyroidectomy, sunitinib, pazopanib, temsirolimus                             Alive
  5                                          53   M   17    Thyroid, pituitary, colon, lung, **cavernous sinus**   42    Thyroidectomy, radiation (clivus), pazopanib                                  Alive
  6                                          49   M   54    **Thyroid**                                            69    Thyroidectomy, radiation (right flank)                                        Alive
  7                                          39   F   173   Thyroid, **adrenal**                                   195   Thyroidectomy                                                                 Alive

Abbreviations: WFBMC, Wake Forest Baptist Medical Center; OS, overall survival; RCC, renal cell carcinoma.

First metastasis bolded if known.

Literature review cohort {#section11-1179554917743981}
------------------------

The systematic review resulted in 6 papers with a total of 72 unique patients with RCC thyroid metastasis. The average age at the time of nephrectomy (which in many patients signified RCC diagnosis) was 56.8 years. The average age at the occurrence of thyroid metastasis was 65.1 years. The median interval between initial RCC diagnosis and thyroid metastasis was 9.7 years. Overall survival for the entire cohort after RCC diagnosis was 17.8 years (95% CI: 13.1-19.5). Overall survival for patients with glandular-only metastasis was 18.8 years (n = 13) and OS for patients with thyroid and nonglandular metastasis was 19.5 years (n = 11), a nonsignificant difference. Median survival after RCC metastasis to the thyroid was 45.6 months or 3.8 years (95% CI: 2.0-5.2).

A comparison of age, sex, interval between RCC diagnosis and thyroid metastasis, as well as survival data between the WFBMC and literature cohorts is shown in [Table 2](#table2-1179554917743981){ref-type="table"}. There was no statistically significant difference in survival between patients with glandular-only vs nonglandular sites of RCC metastasis.

###### 

Characteristics of patients with RCC metastatic to the thyroid gland from the institutional and literature cohorts.

![](10.1177_1179554917743981-table2)

  Comparison of clinical characteristics and survival between WFBMC cohort and literature review cohort                
  ------------------------------------------------------------------------------------------------------- ------------ --------
  Median age at RCC diagnosis, y                                                                          52.4         56.8
  Gender (M:F), %                                                                                         71.5: 28.5   42: 58
  Interval between RCC diagnosis and thyroid metastasis, y                                                4.8          9.7
  OS: entire cohort, y                                                                                    4.7          17.8
  OS: glandular-only metastasis, y                                                                        11.0         18.8
  OS: nonglandular metastasis, y                                                                          3.5          19.5
  OS: after thyroid metastasis, y                                                                         1.8          3.8

Abbreviations: WFBMC, Wake Forest Baptist Medical Center; OS, overall survival; RCC, renal cell carcinoma.

Discussion {#section12-1179554917743981}
==========

Although metastasis to the thyroid remains uncommon, an increasing number of cases are being reported of nonthyroid cancer found in the thyroid gland. Renal cell carcinoma remains the most common cancer to metastasize to the thyroid, with nearly 25% of the cases of metastatic disease in the thyroid attributed to RCC. This can be difficult to identify, as thyroid metastasis in our data set occurred years after initial RCC diagnosis and in some cases after a prolonged disease-free interval, such as the patient case reported above. Furthermore, up to a quarter of patients with RCC treated with a tyrosine kinase inhibitor (TKI) develop thyroid dysfunction, related not to metastasis but instead due to changes in thyroid hormone metabolism and possibly also gland architecture.^[@bibr13-1179554917743981]^ The interplay between thyroid metastasis and TKI-related thyroid dysfunction is not known. Treatment choice and timing of treatment relative to thyroid metastasis was highly variable in both our institutional cohort and in the literature, and thus, this study cannot address this question. Nonetheless, because surgical removal may be beneficial, it is important to consider thyroid metastasis in the differential diagnosis for any patient with a history of RCC and a thyroid nodule.

Metastatic RCC is not classically associated with thyroid involvement, thus studies evaluating this relationship have been limited to case reports and small cohorts. The institutional cohort presented here represents the largest cohort of RCC thyroid metastasis from the United States in the TKI era (2005 onward). Despite our more contemporary cohort, a single-center European cohort of 34 patients with RCC thyroid metastasis identified between 1978 and 2007 similarly reports a median of 6.5 years between initial RCC diagnosis and thyroid metastasis, and in some cases, prolonged survival after thyroid metastasis.^[@bibr14-1179554917743981]^ Many other publications that include RCC thyroid metastasis focus on the types of cancers that metastasize to the thyroid gland, not the clinical characteristics of the patients with these cancers.^[@bibr15-1179554917743981]^ For example, of more than a thousand patients undergoing thyroid surgery at Memorial Sloan Kettering Cancer Center from 1986 to 2005, 21 patients with thyroid metastasis were identified. Of these 21 patients, 10 had RCC, highlighting that solid tumor metastasis to the thyroid is extremely rare but most likely to be from RCC.^[@bibr16-1179554917743981]^ Still other studies have been broad in their approach, for example, investigating RCC metastasis to the head and neck region but not specifically to the thyroid gland^[@bibr17-1179554917743981]^ or investigating RCC metastasis to glandular organs in general.^[@bibr18-1179554917743981]^ Renal cell carcinoma metastasis to the adrenal gland^[@bibr19-1179554917743981]^ and to the pancreas^[@bibr20-1179554917743981]^ has been more thoroughly explored than RCC metastasis to the thyroid, likely in part due to ease of detection of metastasis to these intra-abdominal sites on routine surveillance imaging. Although limited by its retrospective nature and small sample size, the data from the WFBMC cohort of patients with RCC metastasis to the thyroid gland are generally consistent with the data found in the literature. A detailed comparative analysis of the clinical characteristics between the institutional cohort and the patients in the literature, however, was not possible due to small numbers and incomplete or inconsistent data reported.

Why RCC has a propensity to metastasize to the thyroid is not understood. The thyroid gland is very vascular, and it has been suggested that disruption of the blood flow by goiter or thyroiditis predisposes for deposition of metastatic cells.^[@bibr21-1179554917743981],[@bibr22-1179554917743981]^ In contrast, on-treatment thyroid dysfunction has been associated with improved outcomes, although inconsistently.^[@bibr23-1179554917743981],[@bibr24-1179554917743981]^ There may be an explanation to be found in the genotypic analysis of RCC, as intratumor heterogeneity in RCC has been well described.^[@bibr6-1179554917743981]^ Molecular analysis of RCC metastasis to the thyroid may elucidate specific tumor characteristics, and future studies comparing thyroid metastasis with the primary tumors will likely be revealing. Furthermore, there may be an underlying molecular tropism of RCC for glandular organs, especially the thyroid gland, or there may be an advantageous microenvironment in glandular organs for RCC cells. A recent retrospective study compared 138 patients with glandular RCC metastasis to 420 patients with nonglandular RCC metastasis and demonstrated in multivariate analysis that glandular metastasis was an independent prognostic factor for survival.^[@bibr18-1179554917743981]^ Thus, further exploration into mechanisms of glandular metastasis is warranted.

Surgical resection of metastatic cancer is a common treatment option for oligometastatic disease and is often considered in patients who develop metastasis after nephrectomy or as an alternative treatment when systemic therapy fails.^[@bibr18-1179554917743981],[@bibr25-1179554917743981],[@bibr26-1179554917743981]^ Prolonged survival has been suggested in patients with thyroidectomy after diagnosis of metastatic disease from any primary neoplasm.^[@bibr18-1179554917743981]^ From a cohort of 97 patients, 41 had surgical excision of the thyroid after metastatic disease was diagnosed. The median survival for patients who underwent thyroid resection or resection with adjuvant therapy was 30 months, compared with 12 months in those without thyroid surgery (*P* = .09). Although not statistically significant, this does suggest that for patients with isolated metastasis to the thyroid, surgical excision should be considered.^[@bibr26-1179554917743981]^ Furthermore, Alt et al reported that complete resection of all metastatic RCCs coincided with an improved cancer-specific survival of 4.3 years versus 1.3 years in those without complete resection. Interestingly, complete resection led to improved cancer-specific survival in patients who had \>3 metastatic RCC lesions, regardless of whether they were synchronous or asynchronous.^[@bibr25-1179554917743981]^ Prolonged survival after diagnosis of thyroid metastasis suggests that surgery on isolated metastasis may be warranted and necessitates further analysis. This is additionally supported by reports of prolonged survival after surgery for isolated pancreatic and adrenal metastasis from RCC.^[@bibr27-1179554917743981],[@bibr28-1179554917743981]^ Although we did not compare outcomes of patients undergoing metastatectomy with those receiving systemic therapy alone in this analysis, we suggest that thyroidectomy be strongly considered in patients with metastatic disease to the thyroid.

Conclusions {#section13-1179554917743981}
===========

The goal of this work was to describe clinical characteristics of patients with RCC metastatic to the thyroid gland. Due to an unexpectedly small institutional cohort and relatively little published data on this subject, the hypothesis that patients with RCC metastatic to the thyroid has longer survival than those with other patterns of metastasis could not be confirmed. However, the 7 patients described here make this the largest published cohort of patients with thyroid RCC metastases from the United States in the TKI era. Moving forward, it will be important to describe not only the clinical characteristics of the patients but also the molecular and genetic characteristics of both the primary tumor and the metastatic sites.
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